Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review.

ABSTRACT:

Importance

Type I interferon (IFN)-mediated monogenic autoinflammatory disorders (interferonopathies) are childhood-onset rare multisystemic diseases with limited treatment options. The Janus kinase (JAK) inhibitors are promising potential therapeutic candidates for immune-mediated chronic inflammatory skin diseases.

Objective

To review the use of JAK inhibitors to improve decision-making when treating interferonopathies with cutaneous manifestations.

Evidence review

The MEDLINE, EMBASE, CINAHL, Scopus, and Web of Science databases were searched for studies that used JAK protein inhibitors to treat IFN-related monogenic diseases with cutaneous manifestations in humans. The search results are reported using the scoping review approach.

Findings

Seventeen open-la

SUBMITTER: Gomez-Arias PJ 

PROVIDER: S-EPMC8163936 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature